000916864 001__ 916864
000916864 005__ 20230224084256.0
000916864 0247_ $$2doi$$a10.2967/jnumed.121.263202
000916864 0247_ $$2ISSN$$a0097-9058
000916864 0247_ $$2ISSN$$a0022-3123
000916864 0247_ $$2ISSN$$a0161-5505
000916864 0247_ $$2ISSN$$a1535-5667
000916864 0247_ $$2ISSN$$a2159-662X
000916864 0247_ $$2Handle$$a2128/33571
000916864 0247_ $$2pmid$$a35649650
000916864 0247_ $$2WOS$$aWOS:000807305900010
000916864 037__ $$aFZJ-2023-00156
000916864 082__ $$a610
000916864 1001_ $$0P:(DE-HGF)0$$aBarthel, Henryk$$b0
000916864 245__ $$aFuture Directions in Molecular Imaging of Neurodegenerative Disorders
000916864 260__ $$aNew York, NY$$bSoc.$$c2022
000916864 3367_ $$2DRIVER$$aarticle
000916864 3367_ $$2DataCite$$aOutput Types/Journal article
000916864 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1673609495_26271
000916864 3367_ $$2BibTeX$$aARTICLE
000916864 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000916864 3367_ $$00$$2EndNote$$aJournal Article
000916864 520__ $$aThe improvement of existing techniques and the development of new molecular imaging methods are an exciting and rapidly developing field in clinical care and research of neurodegenerative disorders. In the clinic, molecular imaging has the potential to improve early and differential diagnosis and to stratify and monitor therapy in these disorders. Meanwhile, in research, these techniques improve our understanding of the underlying pathophysiology and pathobiochemistry of these disorders and allow for drug testing. This article is an overview on our perspective on future developments in neurodegeneration tracers and the associated imaging technologies. For example, we predict that the current portfolio of β-amyloid and tau aggregate tracers will be improved and supplemented by tracers allowing imaging of other protein aggregation pathologies, such as α-synuclein and transactive response DNA binding protein 43 kDa. Future developments will likely also be observed in imaging neurotransmitter systems. This refers to both offering imaging to a broader population in cases involving the dopaminergic, cholinergic, and serotonergic systems and making possible the imaging of systems not yet explored, such as the glutamate and opioid systems. Tracers will be complemented by improved tracers of neuroinflammation and synaptic density. Technologywise, the use of hybrid PET/MRI, dedicated brain PET, and total-body PET scanners, as well as advanced image acquisition and processing protocols, will open doors toward broader and more efficient clinical use and novel research applications. Molecular imaging has the potential of becoming a standard and essential clinical and research tool to diagnose and study neurodegenerative disorders and to guide treatments. On that road, we will need to redefine the role of molecular imaging in relation to that of emerging blood-based biomarkers. Taken together, the unique features of molecular imaging-that is, the potential to provide direct noninvasive information on the presence, extent, localization, and quantity of molecular pathologic processes in the living body-together with the predicted novel tracer and imaging technology developments, provide optimism about a bright future for this approach to improved care and research on neurodegenerative disorders.
000916864 536__ $$0G:(DE-HGF)POF4-5253$$a5253 - Neuroimaging (POF4-525)$$cPOF4-525$$fPOF IV$$x0
000916864 588__ $$aDataset connected to CrossRef, Journals: juser.fz-juelich.de
000916864 7001_ $$0P:(DE-HGF)0$$aVillemagne, Victor L.$$b1
000916864 7001_ $$0P:(DE-Juel1)177611$$aDrzezga, Alexander$$b2$$ufzj
000916864 773__ $$0PERI:(DE-600)2040222-3$$a10.2967/jnumed.121.263202$$gVol. 63, no. Supplement 1, p. 68S - 74S$$nSupplement 1$$p68S - 74S$$tJournal of nuclear medicine$$v63$$x0097-9058$$y2022
000916864 8564_ $$uhttps://juser.fz-juelich.de/record/916864/files/68S.full.pdf$$yOpenAccess
000916864 909CO $$ooai:juser.fz-juelich.de:916864$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000916864 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)177611$$aForschungszentrum Jülich$$b2$$kFZJ
000916864 9131_ $$0G:(DE-HGF)POF4-525$$1G:(DE-HGF)POF4-520$$2G:(DE-HGF)POF4-500$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$9G:(DE-HGF)POF4-5253$$aDE-HGF$$bKey Technologies$$lNatural, Artificial and Cognitive Information Processing$$vDecoding Brain Organization and Dysfunction$$x0
000916864 9141_ $$y2022
000916864 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-19
000916864 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-19
000916864 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2022-11-19
000916864 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2022-11-19
000916864 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ NUCL MED : 2021$$d2022-11-19
000916864 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bJ NUCL MED : 2021$$d2022-11-19
000916864 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-19
000916864 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2022-11-19
000916864 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-19
000916864 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000916864 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-19
000916864 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2022-11-19
000916864 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-19
000916864 920__ $$lyes
000916864 9201_ $$0I:(DE-Juel1)INM-2-20090406$$kINM-2$$lMolekulare Organisation des Gehirns$$x0
000916864 980__ $$ajournal
000916864 980__ $$aVDB
000916864 980__ $$aUNRESTRICTED
000916864 980__ $$aI:(DE-Juel1)INM-2-20090406
000916864 9801_ $$aFullTexts